4.4 Article

Proton pump inhibitor prophylaxis after Roux-en-Y gastric bypass: A national survey of surgeon practices

Journal

SURGERY FOR OBESITY AND RELATED DISEASES
Volume 19, Issue 4, Pages 303-308

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.soard.2022.10.002

Keywords

Proton pump inhibitor prophylaxis; PPI; Gastric bypass; RYGB; Marginal ulcer; Survey

Categories

Ask authors/readers for more resources

Background: Proton pump inhibitors (PPIs) are commonly used after Roux-en-Y gastric bypass (RYGB) to prevent marginal ulceration. However, the optimal duration of PPI treatment after surgery is unclear. Objective: To assess the practice variability of bariatric surgeons regarding postoperative PPI prophylaxis. Results: The survey showed that PPI administration practices widely varied among surgeons, with different patient selection, medication, dosage, and treatment duration. The study highlights the need for large clinical trials to define optimal practices for PPI prophylaxis after RYGB.
Background: Proton pump inhibitors (PPIs) are frequently used after Roux-en-Y gastric bypass (RYGB) to prevent marginal ulceration. The optimal duration of PPI treatment after surgery to minimize ulcer development is unclear. Objectives: Assess bariatric surgeon practice variability regarding postoperative PPI prophylaxis. Setting: Survey of medical directors of Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program-accredited centers. Methods: Members of the American Society for Metabolic and Bariatric Surgery research committee developed and administered a web-based anonymous survey in November 2021 to bariatric surgeons of Metabolic and Bariatric Surgery Accreditation and Quality Improvement Programaccredited programs detailing questions related to surgeons' use of PPI after RYGB including patient selection, medication, dosage, and treatment duration. Results: The survey was completed by 112 surgeons (response rate: 52.6%). PPIs were prescribed by 85.4% of surgeons for all patients during their hospitalization, 3.9% for selective patients, and 10.7% not at all. After discharge, 90.3% prescribed PPIs. Pantoprazole was most often used during hospitalization (38.5%), while omeprazole was most prescribed (61.7%) after discharge. The duration of postoperative PPI administration varied; it was 3 months in 43.6%, 1 month in 20.2%, and 6 months in 18.6% of patients. Finally, surgeons' practice setting and case volume were not associated with the duration of prophylactic PPI administration after RYGB. Conclusions: PPI administration practices vary widely among surgeons after RYGB, which may be related to the limited comparative evidence and guidelines on best duration of PPI administration. Large prospective clinical trials with objective outcome measures are needed to define optimal practices for PPI prophylaxis after RYGB to maximize clinical benefit. (Surg Obes Relat Dis 2023;19:303-308.) (c) 2023 American Society for Metabolic and Bariatric Surgery. Published by Elsevier Inc. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Surgery

Mucosal and hormonal adaptations after Roux-en-Y gastric bypass

Fauzi Feris, Alison McRae, Todd A. Kellogg, Travis McKenzie, Omar Ghanem, Andres Acosta

Summary: The aim of this study was to review the hormonal and histologic changes observed after RYGB surgery, and to identify gaps and future research directions. The study provides a comprehensive understanding of the food intake regulatory adaptations occurring after RYGB surgery.

SURGERY FOR OBESITY AND RELATED DISEASES (2023)

Article Surgery

Effect of metabolic surgery on immunosuppressive medication use in patients with rheumatic diseases

Pearl Ma, Ahmet Vahibe, Travis McKenzie, Maria D. Hurtado Andrade, Robert A. Vierkant, Kelvin Higa, Michael Kendrick, Omar M. Ghanem

Summary: The study aimed to assess whether metabolic and bariatric surgery (MBS) reduces the use of immunosuppressant agents in patients with rheumatic diseases (RD). The results showed that a significant proportion of patients stopped using prednisone and/or reduced the use of immunosuppressant agents during the follow-up period. The findings of this study indicate that MBS may have a positive impact on the treatment and disease management of patients with rheumatic diseases.

SURGERY FOR OBESITY AND RELATED DISEASES (2023)

Article Surgery

Single-anastomosis duodenoileal bypass with sleeve in the United States: a first comparative safety analysis of the Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program database

Benjamin Clapp, John Corbett, Monica Jordan, Ray Portela, Omar M. Ghanem

Summary: The SADI-S procedure has higher perioperative complications compared to RYGB and SG, but comparable outcomes to BPD/DS.

SURGERY FOR OBESITY AND RELATED DISEASES (2023)

Article Surgery

Evaluating the success of American Society of Metabolic and Bariatric Surgery research grants

Benjamin Clapp, Omar M. Ghanem, Michael Edwards, Spyridon Giannopoulos, Victoria Lyo, Nancy Puzziferri, Dimitrios Stefanidis

Summary: The American Society of Metabolic and Bariatric Surgery (ASMBS) Foundation has been funding competitive proposals by ASMBS members since 2004. This study evaluated the factors associated with grant completion success and the barriers encountered by investigators.

SURGERY FOR OBESITY AND RELATED DISEASES (2023)

Article Surgery

Lumen-apposing metal stents for the treatment of benign gastrointestinal tract strictures: a single-center experience and proposed treatment algorithm

Tala Mahmoud, Azizullah Beran, Fateh Bazerbachi, Reem Matar, Veeravich Jaruvongvanich, Farah Abdul Razzak, Donna Maria Abboud, Eric J. Vargas, John A. Martin, Todd A. Kellogg, Omar M. Ghanem, Bret T. Petersen, Michael J. Levy, Ryan J. Law, Vinay Chandrasekhara, Andrew C. Storm, Louis M. Wong Kee Song, Navtej S. Buttar, Barham K. Abu Dayyeh

Summary: Lumen-apposing metal stents (LAMS) are an effective therapeutic option for the management of benign gastrointestinal strictures, providing high technical and early clinical success. However, a high rate of re-intervention is required after LAMS removal.

SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES (2023)

Editorial Material Surgery

Invited Commentary Anti-Inflammatory Effects of Metabolic Surgery

Omar M. Ghanem

JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS (2023)

Article Surgery

One Anastomosis Gastric Bypass Versus Single Anastomosis Duodenoileostomy with Sleeve: Comparative Analysis of 30-Day Outcomes Using the MBSAQIP

Benjamin Clapp, Kamal Abi Mosleh, John Corbett, Karl Hage, Rachel L. Moore, Helmuth Billy, Jaime Ponce, Omar M. Ghanem

Summary: A retrospective analysis was conducted on patients who underwent SADI-S or OAGB procedures using the MBSAQIP database. The study found that SADI-S had higher readmission rates and more Clavien-Dindo grade 2 and 4b complications.

OBESITY SURGERY (2023)

Article Surgery

Original Patient perspectives on the usefulness of the MBSAQIP Bariatric Surgical Risk/Benefit Calculator: a randomized controlled trial

Spyridon Giannopoulos, Dimitrios I. Athanasiadis, Edward Hernandez, Timothy C. Baumgartner, Bhavani Pokala, Ambar Banerjee, Jennifer N. Choi, Dimitrios Stefanidis

Summary: In a randomized controlled trial, patients undergoing bariatric surgery were divided into two groups, with one group guided by a risk/benefit calculator and the other group receiving traditional surgeon-led counseling. The study found that while most patients found the calculator useful, its use did not influence their procedure choice.

SURGERY FOR OBESITY AND RELATED DISEASES (2023)

Article Surgery

Venous thromboembolism (VTE) prophylaxis after bariatric surgery: a national survey of MBSAQIP director practices

Spyridon Giannopoulos, Seyed Mohammad Kalantar Motamedi, Dimitrios I. Athanasiadis, Benjamin Clapp, Victoria Lyo, Omar Ghanem, Michael Edwards, Nancy Puzziferri, Dimitrios Stefanidis

Summary: Based on a web-based survey, researchers found significant variability in venous thromboembolism (VTE) prophylaxis practices among metabolic/bariatric surgeons, possibly due to limited available evidence. Controversy still exists regarding the ideal methods, dosage, and duration of VTE prophylaxis after metabolic/bariatric surgery. Large prospective clinical trials are necessary to establish optimal practices for risk stratification and prophylaxis of VTE in bariatric surgery patients.

SURGERY FOR OBESITY AND RELATED DISEASES (2023)

Article Surgery

Cholecystectomy After Percutaneous Cholecystostomy for Acute Cholecystitis: Experience and Outcomes in an Academic Practice

Spyridon Giannopoulos, Keith Makhecha, Sathvik Madduri, Felix Garcia, Timothy C. C. Baumgartner, Dimitrios Stefanidis

Summary: Percutaneous cholecystostomy (PC) tube insertion is an effective temporary treatment for acute cholecystitis (AC) before laparoscopic cholecystectomy (LC). The optimal time gap between PC implantation and LC has not been determined. A retrospective analysis of adult patients who underwent PC followed by LC for AC showed that LC was performed after a median of 65 [48 - 96.5] days following PC placement. While no deaths or reoperations occurred within 30 days, some patients required readmission and reintervention. A longer interval between PC and LC did not affect perioperative outcomes but was associated with longer ICU stay.

AMERICAN SURGEON (2023)

Review Gastroenterology & Hepatology

Predictors of marginal ulcer after gastric bypass: a systematic review and meta-analysis

Azizullah Beran, Mohammad Shaear, Saif Al-Mudares, Ishna Sharma, Reem Matar, Mohammad Al-Haddad, Marita Salame, Ray Portela, Benjamin Clapp, Barham K. Abu Dayyeh, Omar M. Ghanem

Summary: This meta-analysis identified predictors of marginal ulcer (MU) after Roux-en-Y gastric bypass (RYGB) and found that Helicobacter pylori (HP) infection, smoking, and diabetes mellitus were significant predictors. Smoking cessation, optimizing glycemic control, and eradication of HP infection can reduce the risk of MU among high-risk patients.

JOURNAL OF GASTROINTESTINAL SURGERY (2023)

Article Surgery

What is the ideal timing of cholecystectomy after percutaneous cholecystostomy for acute cholecystitis?

Spyridon Giannopoulos, Keith Makhecha, Sathvik Madduri, Felix Garcia, Timothy C. Baumgartner, Dimitrios Stefanidis

Summary: Acute cholecystitis is a common disease in clinical practice. Patients who are not suitable for surgery may benefit from early percutaneous cholecystostomy drainage followed by interval cholecystectomy, but the optimal timing between the two procedures is still uncertain. This study aimed to investigate the impact of the duration between percutaneous cholecystostomy and interval cholecystectomy on perioperative outcomes and identify the optimal timing to minimize complications.

SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES (2023)

Letter Surgery

Author response to: Comment on: Risk of non-hormonal cancer after bariatric surgery: meta-analysis of retrospective observational studies

Hayato Nakanishi, Ray Portela, Benjamin Clapp, Omar M. Ghanem

BRITISH JOURNAL OF SURGERY (2023)

No Data Available